Please assess the completion status of the following clinical trial:

Trial Title: Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants with world health organization (WHO)-defined AML, 60 years of age or older, who are unlikely to benefit from standard induction therapy, defined as having at least 1 of the following:~   * Greater than or equal to 75 years of age.~  * Antecedent hematologic disease.~  * Known adverse cytogenetic risk.~  * Eastern Cooperative Oncology Group (ECOG) PS = 2.~  * Participant must not have received definitive treatment for AML, defined as any prior chemotherapy with antileukemic activity.~2. ECOG PS 0 to 2.~3. Expected survival longer than 3 months from enrollment in the study.~4. Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence.~5. Male participants who agree to practice effective barrier contraception or agree to practice true abstinence.~6. Voluntary written consent must be given before performance of any study-related procedure.~7. Suitable venous access for the study-required blood sampling.~8. Clinical laboratory values as specified below within 3 days before the first dose of any study drug:~   •Total bilirubin must be less than or equal to (\<=) the upper limit of the normal range (ULN).~  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be\<=2.5\*ULN.~  * Serum creatinine \<=1.5\*ULN.~  * Albumin greater than or equal to (\>=) 27 grams per liter (g/L).~  * Hemoglobin \>9 grams per deciliter (g/dL). Note: It was permissible to transfuse participants with red blood cells to achieve this criterion.~  * White blood cell (WBC) count less than (\<) 50,000 per microliter (/mcL) before administration of pevonedistat on Days 1, 3, and 5 of Cycle 1.~   Note: Hydroxyurea could be used to control the level of circulating leukemic blast cell counts to no lower than 10,000/mcL while on pevonedistat.~9. Able to undergo bone marrow aspiration and biopsy at screening.~Exclusion Criteria:~1. Previous treatment with azacitidine or decitabine.~2. Known favorable cytogenetic risk.~3. Any serious medical or psychiatric illness.~4. Treatment with any investigational products.~5. Known hypersensitivity to azacitidine or mannitol.~6. Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.~7. Active uncontrolled infection or severe infectious disease.~8. Major surgery within 14 days before the first dose of study drug.~9. Life-threatening illness unrelated to cancer.~10. Clinically uncontrolled central nervous system (CNS) involvement.~11. WBC count greater than (\>) 50,000/ mcL.~12. Prothrombin time (PT) or activated partial thromboplastin time (aPTT) \>1.5\* ULN or a history of coagulopathy or bleeding disorder~13. Known human immunodeficiency virus (HIV) positive.~14. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection~15. Known hepatic cirrhosis or severe pre-existing hepatic impairment.~16. Known cardiac/cardiopulmonary disease defined as 1 of the following:~    * Uncontrolled high blood pressure (that is, systolic blood pressure \>180 milliliter per mercury (mm Hg), diastolic blood pressure \>95 mm Hg).~   * Congestive heart failure New York Heart Association (NYHA) Class III or IV, or Class II with a recent decompensation that required hospitalization or referral to a heart failure clinic within 4 weeks before screening (see Section 15.4 of the protocol in Appendix 16.1.1).~   * Cardiomyopathy or history of ischemic heart disease~   * Participants with ischemic heart disease who had acute coronary syndrome (ACS), myocardial infarction (MI), and/or revascularization (example, coronary artery bypass graft, stent) in the past 6 months were excluded. However, participants with ischemic heart disease who had ACS, MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms could be enrolled.~   * Arrhythmia (example, history of polymorphic ventricular fibrillation or torsade de pointes). However, participants with \<Grade 3 atrial fibrillation (a fib) for a period of at least 6 months could enroll. Grade 3 a fib is symptomatic and incompletely controlled medically, or controlled with device (example, pacemaker), or ablation. Participants with paroxysmal a fib were permitted to enroll.~   * Implantable cardioverter defibrillator.~   * Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing).~   * Pulmonary arterial hypertension. Prolonged rate corrected QT (QTc) interval \>= 500 msec, calculated according to institutional guidelines~17. Left ventricular ejection fraction~18. Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis.~19. Body mass index \>40 kilogram per square meter (kg/m\^2).~20. Treatment with CYP3A inducers within 14 days before the first dose of MLN4924.~21. Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of study drug, except for hydroxyurea.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MLN4924 and Azacitidine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).